

Myobloc® (rimabotulinumtoxinB)

When requesting Myobloc® (rimabotulinumtoxinB), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications and meet the specific coverage guidelines for the covered indications.

FDA-approved Indications

- Treatment of adults with cervical dystonia.
- Treatment of adults with chronic sialorrhea.

Coverage Guidelines

The individual must be 18 years of age or older for approval of the following indications:

- Cervical dystonia
- Chronic sialorrhea

Approval duration: 12 months

Recommended Dosing

Cervical Dystonia

Recommended up to a maximum dose of 5,000 units, divided among affected muscles, administered not more frequently than once every 12 weeks.

Chronic Sialorrhea

Recommended up to a maximum dose of 3,500 units, divided among the parotid and submandibular glands, administered not more frequently than once every 12 weeks.

References

1. Myobloc® (rimabotulinumtoxinB) [prescribing information]. South San Francisco, CA: Solstice Neurosciences, Inc.; March 2021.
2. RimabotulinumtoxinB (Myobloc®). Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. [Updated; April 30, 2021; Accessed June 3, 2021].
3. Simpson, DN et al. Practice guideline update summary. Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86(19):1818-1826.